Compounding Centers get new and more regulations
October 25th, 2016 by Peter CalcottI just had an article describing the Compounding industry and what the FDA is doing about it. Here is the link.
I just had an article describing the Compounding industry and what the FDA is doing about it. Here is the link.
Do you have deviations that just won’t go away? Do they disappear for a couple of months only to reappear a few months later stronger than ever? Have you ever wondered why?
I won’t try to say that there is one cause for this but one that I have found continuously is Human Error as a major cause of the problem. The obvious CAPA for this observation is to retrain the operator and rewrite the SOP. I have seen it often in companies.
When I go in to audit the QMS, this is one area I look for first. I look at the CAPAs and tally up the retrain operator and the rewrite SOP ones and if I find it happens more than 10% of the time, I know where to focus. Investigations are not thorough or in depth.
On a recent visit to a client, they had just exited from a grueling inspection by an agency with a total of 53 observations. They had developed their responses which are really CAPAs in any other language. There were a total of 135 CAPAs and 55% were “retrain operator” or “rewrite SOP”. I asked the person in charge of getting the responses back and asked whether he thought it would correct the problem. His reply was an honest “No, many of these problems we’ve seen before and tried that and it never works”. So, I ask him why are you doing it again, remembering Einstein’s quote “insanity is doing the same thing again and expecting a different result”. At least I think it’s Einstein.
I then asked, “Why did you do this when you know it will not work?” The answer was a chilling “because the regulators will accept it and it will allow me to get back to making product!” I wanted to say “Yes, in the same broken way as before”.
After talking with other people at the plant it became clear that their investigation skills and tools were deficient. They could get to the human error point. They recognized that somebody had made an error but they lacked the tools to investigate further as to why it occurred. Was it a system that was defective, were the operators overloaded with work, were the work stations organized appropriately?
Very rarely is Human Error the root cause but rather Human Error is the symptom of things not functioning properly. It is often the result of a deficiency elsewhere. No other industry accepts human error just our pharmaceutical one.
There are four main ways that that things fail and manifest as human errors. There has been plenty of research in this area but not in pharmaceuticals.
As you read through the examples above, you will see a lot of similarity and overlap and that is because, it is rarely only one of the above that fails. It actually starts at the management level with culture. They set the tone that creates the systems, procedures and people to fail.
So how can you detect that you have a culture problem? A systems problem? Poor procedures? Or people prone to human errors?
You know you have problem or potentially one if you can say yes to any of the following:
Culture Problems include
System problems are evident by these
Procedure problems are exemplified by
Which brings us to People
Of course this is not a comprehensive list but you get the picture!!
To get rid of all these types of problem requires both management and workers to take responsibility. We must move to a culture exemplified by
The road is a long one fraught with challenges but as my father used to wisely tell me “Knowing you have a problem is 50% of the way to solving it”. How true!!!!
You’ve heard of it. You’ve probably experienced it. You may even have survived it. Yes, I am talking about “Project Operations Excellence”. Don’t get me wrong. The principles behind it are very good, even admirable. The premise is that we are operating presently as a result of processes that have evolved over time. A Band-Aid here, a Band-Aid there. The result is a set of processes that are inefficient not targeted to the customer and to be honest often counterproductive, sometimes counterintuitive. It does not sound good, does it?
Wouldn’t it be wonderful if we could deconstruct our processes and start again? That is what these companies sell you. The promised land of operations that are logical, lean (which brings me to another element of this concept, but I’m not getting drawn into that now – hint it suffers some of the same issues), lacking in superfluity, less is more, you get my drift.
So you sign on the dotted line and then in come the saviors. Most often it’s not the A team that did the sales pitch, the Dog and Pony show but if you are lucky it’s the C or D team. A couple of people who’ve seen the inside of an operations for a couple of hours together with a band of neophytes, fresh out of MBA school. They know the jargon, are excellent at powerpoints (I think that is one of the majors), the theory is at their command. Practical experience gained from case studies, that never go wrong.
Don’t I sound cynical and negative? No actually, I am not cynical or negative. I did not expect anything else. I’ve been through this exercise 5 or 6 times at different companies using some of the industry best companies and I’ve seen it at some of the companies I consult with. The problem is that we are our worst enemies. We do not challenge these saviors with data or facts or our experience. Just because they conclude something, does not mean it’s the best idea. It is an idea that should be considered. But often in these short 30 minute interviews to gather their data, they do not gather all the right information, they do not ask the right questions. Often it seems like they have gone in to these companies with the answer and are gathering data to support the results.
An example that came up recently, when talking with a client, related to an operational set up of a piece of equipment. On first glance, it appeared that after the equipment was set up, and then it was checked twice before using. The saviors immediately pointed out duplication and eliminated the second assessment. Nobody asked the question of why there were two checks. The junior person being interrogated did not have the answer. Voila, the step was removed. It was only afterwards, that a more senior person with experience of when the second check was put in place, that the explanation was clear. This piece of equipment had a tendency to drift in setting and the second check just before use was to monitor whether it had or not.
Perhaps the first check could have been removed? But that was never asked. An A team member with good process experience might have caught that one.
Modern day root cause analysis contends that silver bullets do not exist. Rather it is a series of events (each incapable of causing the problem themselves) align and it is this alignment that causes the event. So often we end up with corrective actions which are several to improve each element.
Is this example given an isolated incident? I contend no, because I have been into many companies reeling from these assessments. In fact one company that is in regulatory trouble now can trace their decrease in performance in operations, to an Operations Excellence episode. The results of the study were taken as gospel and implemented blindly. Clearly, all were at fault. An incomplete analysis, and accepting everything as correct etc.
So I caution everybody to think through how you manage an Operations Excellence project.
Remember that these people coming in to assess do their work and leave. They do not have to operate with what they leave. They are like a flock of seagulls, they fly in, squawking, leave you a present (hint, it is not paper) and fly off. What you should be looking for with an Operation Excellence is a team to evaluate, propose solutions and help you implement. And make sure you get the A team.
In the first quarter of 2014, 3 Indian companies were issued warning letter (see my posting on the blog) whereas 7 pharmacies were hit. Statistically significant? Perhaps.
After the debacle of the New England Compounding Center about a year ago, the FDA has been on a rampage in the Pharmacy world. I am no lawyer but the way I read it is the pharmacies are using a loophole in the law centered around the issues of FDA jurisdiction. FDA basically regulates interstate distribution of drugs, so make a drug in state X and “export” it to state Y – yep FDA has jurisdiction. So the manufacturers of drugs are under FDA rule.
Now, pharmacies are allowed to take these drugs and dispense prescriptions. So when you go to your corner pharmacist, you can see them dispensing. Counting out pills and putting them into bottles. Hardly much risk here so long as they don’t muddle them up, get them cross contaminated etc. But they can also do further dispensing. For instance, they can take a sterile vial or bottle of a drug and dispense it to another sterile container. Now this is another matter. What we are describing is aseptic processing. As we all know that’s a risky business. How many manufacturers fall foul of the regulations in industry? The number of warning letters are numerous.
But it seems that FDA can not step in unless there is a demonstrated safety calamity. But we don’t want to wait for that each and every time. So what can the FDA do? Their tack is to inspect these operations when they suspect that the Pharmacy has overstepped their authority. It seems that in a majority of the 7 letter this quarter they have seen that the pharmacies have been dispensing these aseptically prepared drugs without prescriptions and compounding several drugs together. Some of these drugs have different regimes of taking the drug. Ergo, they are no longer dispensing, but manufacturing.
Now when they go in and inspect they cite for lack of GMP adherences and the story goes on. Call me naive, but if I go to a pharmacy, I want an assurance that the drugs I am receiving are not adulterated. I don’t care who regulates them but I want it done properly. Clearly the Boards of Pharmacy have not been doing a good job (they are the ones who regulate at a state level rather than FDA). What we have here is a standard clash between Federal and state control – we see it every day in other matters but in this case they are using our health as a pawn in the game.
Keep up the good work FDA.
He is the link to the 7 warning letters
Nora Apothecary Services , Lowlite Investments DBA Olympia Pharmacy, Pallimed Solutions, Wedgewood Village Pharmacy, Total Pharmacy Services ,Avella of Deer Valley, Village Fertility Pharmacy
In the first quarter of 2014, there are 3 warning letters for Indian Companies. Add to that the travails of Wockhardt and Ranbaxy over the last couple of years and it looks bleak for Indian Companies in general. I regularly read LinkedIn Groups and I noticed a thread related the question of reliability of Indian Medicines.
Can We trust Indian Drug Companies?
It created a firestorm of responses, many of which were from India. The responses fell into three categories which I will paraphrase
1. The FDA is picking on us – EU and US companies have the same problems
2. I would never take an Indian medicine again
3. Indan regulators find no problem who is the FDA to tell us what our standard should be
1. Of course some US and EU and other country companies have run foul of the law. Actually there are over twice the number of warning letters directed to Pharmacies than Indian companies in Q1. So maybe the FDA is picking on a broader range of companies. Or putting it another way – they are doing their job and hard one it is.
2. Are all Indian companies bad? Of course not. I do not know the statistics but I have heard that 50% (and it could be higher or lower) of the US generics is from India and undoubtedly the major are fine (at least I hope so).
3. I am sorry but if you want to sell drugs on the US market you have to play by the rules here. On paper, the Indian regulations are as tough as the FDAs but the question is detection of issues and enforcement that will separate the theory from the reality.
So what are the issues that are found
UVS issues appear to relate to data integrity. Check my previous posting on the blog . The link to the warning letter is here.
Smruthi Organics Ltd has a Warning Letter with only 3 observations. One centered on data deletion, record destruction and inadequate investigations. The link is here
Canton Laboratories Private LTD has a warning letter with 4 observations. The essence is failure to keep data from testing, failure to actually test, failure to adequately clean equipment and failure to manufacture according to instructions and keep adequate records.. The link to the Warning Letter is here
In reality there is a lot of similarity in all these observations. It does make one wonder about the quality of medicines. Is this the tip of the iceberg? Should I be worried?